Life sciences firms' likelihood of developing intellectual property in the U.S. 2018
This statistic depicts the percentage of medtech and biopharma firms that are likely to move or locate intellectual property back to the U.S. after the U.S. tax reform, according to a survey conducted during summer 2018. According to the survey, 10 percent of companies are significantly unlikely to move their intellectual property back to the U.S. at that time.